Cystic fibrosis patients in limbo as pharma company and HSE argue over drug price deal

Fiadh and Caoimhe Ní Luing at the launch of 65 Roses Day for CF Ireland. Picture: Shane O'Neill

Young children in need of a revolutionary drug for cystic fibrosis (CF) have been left in limbo as the HSE and the pharmaceutical company argue over the extension of an existing drug-price deal.

It has now been one month since the parents of 35 children, aged between six and 11, discovered their children are not included in the expanded roll-out of the wonderdrug Kaftrio, manufactured by Vertex.